Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  • End date
    Jun 26, 2022
  • participants needed
  • sponsor
    Groupe Francophone des Myelodysplasies
Updated on 26 January 2021
Marie Robin, MD
Primary Contact
GHEF, site de Meaux (0.9 mi away) Contact
+65 other location
cell transplantation
blood transfusion


Comparison of survival in patients with or without a matched donor at 36 months


Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation.

Patients without a matched donor received the best available treatment. All patients will be followed at least 36 months or until the end of the study.

Condition miller-dieker syndrome, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS), MDS, myelodysplastic syndromes, myelodysplastic syndrome (mds)
Treatment Transplantation
Clinical Study IdentifierNCT02757989
SponsorGroupe Francophone des Myelodysplasies
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Signed Informed consent
Classical IPSS intermediate 1 or low myelodysplastic syndrome associated with at least one poor prognosis feature
Intermediate or higher risk revised IPSS
RBC transfusion dependent anemia and failure to 2 or more lines or therapy (including EPO, Lenalidomide or demethylating agent)
thrombocytopenia < 20 G/L requiring transfusion
neutropenia < 0.5 G/L associated with severe infection (defined as requiring hospitalization)
Patient aged 18 and < 70 years For young patients, 18-45 years, Fanconi disease and dyskeratosis should be ruled out
Patient for whom a transplantation from a matched donor, (8/8 (HLA A, B, C, DRB1) identical at molecular level)unrelated donor or matched sibling), is considered irrespective of donor availability
Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale (At time of screening)
Negative pregnancy and adequate contraception (including in male patients wishing to father), if relevant
Wash-out of at least 30 days since a previous treatment with Vidaza, Lenalidomide, EPO or any other treatment inducing cytopenias

Exclusion Criteria

MDS classified according to classical IPSS as intermediate 2 or High risk
Transformation in Acute myeloid Leukemia (AML)
Severe active infection or any other uncontrolled severe condition
Organ dysfunctions including the following
Hepatic : total bilirubin > 2 times upper limit of normal (ULN) (except moderate unconjugated hyperbilirubinemia due to intra medullary hemolysis or Gilbert syndrome) , alanine transaminase (ALT) and aspartate transaminase (AST) > 3xULN
Symptomatic respiratory chronic failure
Symptomatic cardiac failure
Renal clearance < 60ml/min
Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or other tumors if not active during the last 3 years)
MDS with the following causal germline disease : Fanconi anemia, GATA2 related syndromes and telomere disorders
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note